乐伐替尼对晚期肝癌大鼠血清b-FGF、VEGF及生存时间的影响分析

Effects of Lenvatinib on serum b-FGF, VEGF and survival time in rats with advanced liver cancer

目的 :研究乐伐替尼对晚期肝癌大鼠血清b-FGF、VEGF及生存时间的影响。方法 :将40只SD大鼠随机分为4组,正常组(A组),模型组(B组),低剂量组(L组),高剂量组(H组),每组10只。L组给药乐伐替尼(2mg/kg,溶于0.1mL生理盐水),H组给药乐伐替尼(4mg/kg,溶于0.1mL生理盐水),正常组和模型组给予同等剂量生理盐水。观察各组大鼠治疗第1d,10d,20d的血清b-FGF、VEGF浓度,观察并记录各组大鼠治疗期间自主活动次数及生存时间。结果 :A组大鼠血清b-FGF、VEGF浓度并无较大波动,B组大鼠血清b-FGF、VEGF浓度随疾病进展浓度升高,L组,H组大鼠血清b-FGF、VEGF浓度与B组相比均有不同程度的下降,差异有统计学意义,且H组比L组下降幅度大,差异有统计学意义;B组大鼠自主活动次数随时间推移,次数逐渐减少,L组,H组与B组相比,大鼠自主活动次数均不同程度增加,H组>L组;B组最早出现死亡个体,且最早全部死亡,与B组相比,L组,H组生存时间均延长,其中H组>L组。结论 :乐伐替尼能降低晚期肝癌大鼠血清b-FGF、VEGF的浓度,增加肝癌大鼠自主活动次数,延长生存时间。

Objective To study the effect of Lenvatinib on serum b-FGF, VEGF and survival time in advanced liver cancer rats. Methods 40 SD rats were randomly divided into 4 groups: normal group(group A), model group(group B), low dose group(group L), high dose group(groupH), 10 rats in each group. Group L was administered Lenvatinib(2 mg/kg, dissolved in 0.1 m L physiological saline), H group(4 mg/kg, dissolved in 0.1 m L physiological saline), normal group and model group were given the same dose of normal saline. The serum b-FGF and VEGF concentrations of rats treated with 1 D, 10 d and 20 d were observed, and the number of voluntary activities and survival time in each group during treatment were recorded and recorded. Results The rats in group A serum b-FGF and VEGF concentrations had no greater volatility, the rats of group B serum b-FGF and VEGF concentration with the progression of the increase of the concentration of L group, H group of rats serum b-FGF and VEGF concentrations compared with the B group were decreased, the difference was statistically significant, and H group than in L group the large decline, the difference was statistically significant;locomotor activity of rats in the B group number over time, gradually reduced the number, L group, H group compared with B group, the number of independent activity in rats with different degrees of increase, H group and >L group;B group as early as the death of individuals, and the earliest died, compared with B group, L group, H group, survival time was prolonged, the H group >L group. Conclusion Lenvatinib can reduce the concentration of serum b-FGF and VEGF in rats with advanced liver cancer, increase the number of autonomic activities and prolong the survival time of HCC rats.